Mixed phenotype acute leukemia ( 
Abstract:
Mixed phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible. A variety of different terms and classification systems have been used historically to describe this entity. MPAL is currently defined by a limited set of lineage-specific markers proposed in the 2008 WHO monograph on classification of tumors of hematopoietic and lymphoid tissues. In adult patients MPAL is characterized by relative therapeutic resistance that may be attributed in part to the high proportion of patients with adverse cytogenetic abnormalities. No prospective, controlled trials exist to guide therapy. The limited available data suggests that an 'acute lymphoblastic leukemia-like' regimen followed by allogeneic stem cell transplant may be advisable; addition of a tyrosine kinase inhibitor in patients with t(9;22) translocation is recommended. The role of immunophenotypic and genetic markers in guiding chemotherapy choice and post remission strategy as well as the utility of targeted therapies in non-Ph positive MPALs are unknown.
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Introduction
The absence of essentially any useful prospectively collected data on how to treat mixed phenotypic acute leukemia (MPAL) in adults both simplifies and complicates any discussion of this topic. Given little truly useful information, we have derived an approach that is based on data in the literature, makes logical sense, and can be adhered to: once MPAL is definitely identified patients should be treated according to an 'acute lymphoid leukemia' type induction regimen followed by allogeneic stem cell transplant (alloSCT) in responding patients if feasible.
What is Mixed Phenotype Acute Leukemia?
Patients who are diagnosed with acute leukemia (greater than 20% blasts in blood or marrow, or fewer in the case of certain chromosomal translocations or an extramedullary presentation) can generally be classified as having either myeloid lineage-derived disease (AML) or lymphoid lineage-derived disease (ALL).
Occasionally the immature cells display cytochemical and/or immunophenotypic features of both lineages (biphenotypic) or there are different populations of leukemia cells (bilineal) . The distinction between bilineal and biphenotypic leukemias is often blurred, especially given the fact that 'two populations' of cells perhaps represent subclones derived from a unique stem cell. Accordingly, this distinction does not generally affect our diagnostic or therapeutic approach.
Two important recent algorithms have been used to define this entity. In the first of these (1995) , the European Group for Immunological Characterization of Acute Leukemias (EGIL) developed a scoring algorithm in which a point system determined whether or not a patient had enough immunophenotypic variety to qualify as biphenotypic (see Figure 2A) 1,2 . The second and most recent 2008 WHO monograph on classification of tumors of hematopoietic and lymphoid tissues includes a helpful chapter on acute leukemias of ambiguous lineage, "leukemias that show no clear evidence of differentiation along a single lineage" 3 .
These encompass both MPAL, the primary topic of this review, but also acute undifferentiated leukemia (AUL) wherein the malignant cells do not express lineage-specific antigens. This classification ( Figure 2B ) tries to minimize the difficult distinction between bilineal and biphenotypic leukemia and subclassifies these promiscuously derived cells as usually either B-myeloid or T-myeloid.
MPAL that harbor Philadelphia chromosome (Ph+) or MLL rearrangements are considered a distinct diagnostic subgroup ( Figure 2B ). An important point is that
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From AML-defining balanced translocations such as t(8;21), a type of favorable prognosis AML which frequently expresses multiple B cell markers 4 , are not considered biphenotypic. It also excludes secondary leukemias (arising after prior cancer therapy or myelodysplasia), leukemias with FGFR1 mutations which have features of both T lymphoid and myeloid differentiation, and chronic myeloid leukemia (CML) in blast crisis which can present with a variety of lineages. The latter is sometimes difficult to separate from Ph+ MPAL (that may actually represent transformation from a previously undiagnosed chronic phase CML).
The essential feature of MPAL (figure 2B) is that cells express lineage specific myeloid markers as well as lineage specific T or B lymphoid markers. Although there are caveats (see legend to figure 2B), CD3 expression equals T-lymphoid development and CD19 plus one or two other markers suggest B-lymphoid origin.
Myeloid origin can be determined with a set of monocytic markers or more commonly by MPO expression. Although various thresholds for flow-based MPO positivity were introduced over the years (e.g. 10% of blast population 1,5 ), no specific threshold has been acknowledged in the 2008 WHO monograph 3, 6 .
As compared to the EGIL classification, the 2008 WHO classification utilizes a more limited set of lineage markers that can be more consistently applied. In 2015, the 2008 WHO classification still remains the most practical means to define and sub-classify MPAL, but hopefully advances in deciphering the molecular pathogenesis of acute leukemia will soon lead to a more robust approach to the diagnosis of these entities. 
Risk factors and outcomes:
The reasons underlying resistance to therapy in this heterogeneous group are not clear but may be related to the high prevalence of drug efflux pump expression 
Treatment of MPAL
There are no prospective trials that point to an optimal strategy. Beyond one's own experience, we are left with heterogeneous case series which describe outcomes retrospectively. Further complicating data interpretation is the inclusion of patients with well-defined AML syndromes in previous classifications (such as core binding factor leukemias) that may bias those reports towards the use of AML type therapy. Case studies from individual centers or countries tend to examine all cases of acute leukemia and describe MPAL in 2-3%. While these studies probably fairly accurately reflect the true incidence of the entity, treatment decisions are haphazard and are subject to unknown bias regarding individual physicians, since there was no widespread treatment 'policy'. The few studies which retrospectively garnered MPAL cases from cooperative group trials use more homogeneous treatments, but inevitably have excluded cases from eligibility based on ambiguity.
One won't find much guidance in the NCCN guidelines either. The precise definition of which cases should be treated according to the ALL vs. AML guidelines is sidestepped. The reader is advised to consult a center or individual with experience in diagnosing these entities 51 . As someone who serves on the AML NCCN guidelines committee (RMS); I readily admit personal uncertainly which can be blamed on the lack of evidence.
Caveats aside, the dilemma when considering a patient who is a bona fide case of As this disease is believed to emanate from a proximal, presumed long-lived stem cell in the hematopoietic hierarchy (high level of CD34 expression, capable of lineage switch or infidelity), one could surmise that chemotherapy alone would be insufficient to eradicate the disease. Ph+ ALL and MDS-associated and/or adverse chromosome AML are historically incurable without a stem cell transplant; the same likely applies to MPAL. Moreover, the inclusion of more chemotherapeutic agents in upfront therapy used in an ALL or combined regimen would seem more logical than an AML regimen, especially latter's use of ara-C, less useful against a slowly dividing primitive stem cell. Ideally one could inhibit the gene product of a 'founder' mutation present early in disease development and throughout the course. This serendipitous situation appears to be the case for Ph+ MPAL.
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Ph+ and MLL rearranged MPAL
The only 'special' cases within the MPAL WHO framework are patients with 27, 40, 41, [44] [45] [46] and some reports found these regimens to be rather toxic 40, 44 . could be treated with consolidation chemotherapy rather than alloSCT in a similar fashion to Ph+ ALL that becomes molecularly negative after therapy.
Summary
As shown in Figure 3 , a reasonable approach to a patient with MPAL is to first determine if the disease is driven by BCR-ABL1. If so, age appropriate ALL therapy plus a TKI followed by SCT is reasonable. If BCR-ABL1 negative, age appropriate ALL therapy followed by SCT after remission is an acceptable strategy. Important areas for further study are: 1) whether the degree of MPO positivity by immunophenotype /cytochemistry should influence the choice of therapy; 2) whether the presence of myeloid specific mutations or other genetic and molecular markers should be considered; 3) can the pathophysiology of 11q23 leukemia be successfully exploited and 4) will allo SCT be needed for MPAL t(9;22) patients who respond very well to chemotherapy plus TKI?
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Case-Part 2
Based on immunophenotype and cytogenetic information, the diagnosis of MPAL with t(9;22)(q34;q11.2); BCR-ABL1 was made. 
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: The following lineage defining markers are required for assigning more than one lineage to a single blast population: 1) Myeloid lineage: myeloperoxidase (by flow cytometry, immunohistochemistry or cytochemistry) or monocytic differentiation (diffuse positivity for non-specific esterase or expression of at least 2 of the following: CD11c, CD14, CD36, CD64, lysozyme).
2) T-lineage: cytoplasmatic CD3 (flow cytometry with antibodies to CD3 epsilon chain; caution when using polyclonal anti-CD3 in immunohistochemistry as it may not be specific) or surface CD3.
3) B-lineage: strong CD19 with at least 1 of the following strongly expressed: CD79a, cytoplasmatic CD22, CD10 or weak CD19 with at least 2 of the following strongly expressed: CD79a, cytoplasmatic CD22, CD10.
For bilineal MPAL the myeloid component can be recognized when there are 2 or more distinct populations of blasts, one of which would meet the criteria for AML (need not comprise >20% of nucleated cells). c The following subgroups of leukemia should be defined primarily by their genetic or clinical features even if they satisfy the above requirements for mutli-lineage expression. A secondary notion regarding their mixed phenotype should be added: AML with recurrent cytogenetic abnormalities such as t(8;21), t(15;17) or inv(16), leukemia with FGFR1 mutations, chronic myeloid leukemia in blast crisis, myelodysplasia-related AML and therapy related AML. Include rare cases where leukemic blasts show evidence of both T and B lineage, trilineage T, B and myeloid commitment or other rare combinations; CD79a and CD10 should not be considered as evidence for B cell differentiation in this setting as they lack specifity. e These diagnostic entities are associated with lack of definitive lineage commitment. 'Acute undifferentiated leukemia' include leukemias that express no lineage specific markers. 'Other ambiguous lineage leukemia' subgroup encompass the rare cases of leukemia that express combination of lineage associated markers that are suggestive but not sufficient for lineage assignment (so called 'acute unclassifiable leukemias'); Natural killer cell lymphoblastic leukemia/lymphoma is regarded as a provisional entity in this category.
